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BMRF2documented to encode for ten envelope glycoproteins, gB, gH, gL, gM, gN, gp350,
gp42, gp78, gp150 and BMRF2. The BDLF2 open reading frame is also predicted to encode a type II membrane
protein but, although found in the virion, it has been described as a component of the tegument. We show
here that, as predicted, it is the eleventh envelope glycoprotein of the virus. The full length 65 kDa
glycoprotein formed a complex with BMRF2 and, as its homologs in other gammaherpesviruses, was
dependent on BMRF2, for authentic processing and transport. Two cleavage products of BDLF2 were also
identiﬁed in cells and in puriﬁed virion particles, one corresponding approximately to the aminoterminal half
of the protein, that remained associated with the full length form, and one corresponding to the
carboxyterminal glycosylated portion of the protein which did not.
© 2008 Elsevier Inc. All rights reserved.IntroductionEpstein–Barr virus (EBV) is one of eight known human herpes-
viruses and, like all these large DNA viruses, has a virion comprised of
a tegumented, icosahedral nucleocapsid surrounded by an envelope
containing multiple glycoproteins of variable structure. Proteomic
analysis of the EBV virion (Johannsen et al., 2004) has conﬁrmed and
extended previous studies indicating the presence of at least nine
unique glycoprotein species, gp350, gB, gH, gL, gp42, gp150, gp78, gN
and gM. Very small amounts of a tenth glycoprotein, BMRF2, which
has been reported to be virion associated (Xiao et al., 2007), were also
detectable. In silico analysis of EBV open reading frames (Baer et al.,
1984) does, however, suggest that one additional protein, detected in
the virion but annotated as a tegument protein, might be an eleventh
envelope glycoprotein. The BDLF2 open reading frame is predicted to
encode a 420 amino acid protein with a transmembrane domain
between residues 182 and 208. Six potential N-linked glycosylation
sites are predicted in the carboxyterminal half of the sequence, which,
if modiﬁed, would indicate that the BDLF2 gene encodes a type two
virion envelope glycoprotein.
Homologs of the BDLF2 gene are found only in the gammaher-
pesviruses and have not been extensively studied. Most is known
about the BDLF2 homolog in the murine herpesvirus gamma 68
(MHV-68) which is an envelope protein, gp48, that is the product of
open reading frame 27 (ORF27). Authentic processing of gp48 and itsr).
l rights reserved.transport from the endoplasmic reticulum to the cell membrane can,
however, only occur if it is expressed coordinately with the MHV-68
gene ORF58 (May et al., 2005a). ORF58 encodes a multispan
membrane glycoprotein which is in turn the homolog of EBV BMRF2
(Virgin et al., 1997). Glycoprotein gp48 is not essential for MHV-68
lytic replication, but it contributes signiﬁcantly to intercellular virus
spread (May et al., 2005b). This is of particular interest with respect to
the potential role of BDLF2 in EBV infection, should BDLF2 also interact
with BMRF2. The BMRF2 protein plays an important role in efﬁcient
infection of polarized epithelial cells (Tugizov et al., 2003), despite the
fact that it is probably not essential for attachment (Borza et al., 2004;
Molesworth et al., 2000; Oda et al., 2000) nor fusion (McShane and
Longnecker, 2004), implying a role perhaps similar to that of the
ORF27/ORF58 complex of MHV-68, one that has been suggested to be
compatible with the low level detection of BMRF2 in the virion
(Johannsen et al., 2004).
We report here that the protein encoded by the BDLF2 gene is
indeed the eleventh and ﬁnal EBV envelope glycoprotein and that, like
its homolog in MHV-68 its processing and transport, is dependent on
coexpression with BMRF2.
Results
Localization of BDLF2 is altered by coexpression with BMRF2
Three antibodies were made to examine the expression of the
BDLF2 and BMRF2 proteins by immunization of rabbits with GST
fusion proteins. The antibodies to BDLF2 were made to GST fused to
Fig. 1. Effect of BMRF2 on localization of BDLF2 in transfected cells. (A) Linear map of the predicted BDLF2 protein indicating positions of the transmembrane domain (black disk), the
potential N-linked glycosylation sites (lollipops) and the sequences included in the GST fusion proteins (grey rectangles) used to make antibodies to the aminoterminus (αBDLF2-N)
or carboxyterminus (αBDLF2-C). (B) Indirect immunoﬂuorescence of CV-1 cells transfected with pTM1-BDLF2, pTM1-BMRF2 or pTM1-BDLF2 and pTM1-BMRF2 as indicated. Cells
were stained with antibodies to the aminoterminus of BDLF2 (αBDLF2-N) or to BMRF2 (αBMRF2).
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ﬂanked the predicted transmembrane domain (Fig.1A) and antibodies
to BMRF2 (αBMRF2) were made to GST fused to residues 173–217 as
described by Tugizov et al (2003). These BMRF2 residues, which
include an RGD motif, are exposed and bind to integrins (Xiao et al.,
2008). To conﬁrm that each antibody recognized its cognate protein,
the BDLF2 and BMRF2 genes were cloned into the pTM1 vector for
expression under control of the T7 promoter in cells concurrently
infected with a vaccinia virus expressing the T7 polymerase. Diffuse
staining with αBMRF2 was seen both in the cytoplasm and at the
membrane (Fig. 1B) as previously described for this protein expressed
either alone or in virus-producing cells (Xiao et al., 2007). AntibodyFig. 2. Expression of BDLF2 and BMRF2 in the absence of other virus proteins. SDS–PAGE
(αBDLF2-N) or antibody to BMRF2 (αBMRF2) from CV-1 cells labeled with [3H] leucine and tr
mock-digested, digested with endoglycosidase H (Endo H) or digested with PNGase F before
asterisks.αBDLF2-C (though not preimmune antibody from the same rabbit)
reacted almost as strongly with cells transfected with pTM1-BDLF2 as
with cells transfected with pTM1 (not shown). Subsequent analyses
(Fig. 3) revealed that the carboxyterminal GST fusion protein induced
reactivity with a cell protein and immunizations of rabbits were
stopped as inﬂammation at injection sites became a problem.
Antibody αBDLF2-N, however, reacted well and speciﬁcally with
cells transfected with BDLF2 (Fig.1B), but, although someweak diffuse
staining was seen, most staining was strong and strikingly located to
large cytoplasmic aggregates. Coexpression of BDLF2 and BMRF2
relocated the staining from these intracellular aggregates to a smooth
rim at the cell surface.analysis of proteins immunoprecipitated by antibody to the aminoterminus of BDLF2
ansfected with pTM1-BDLF2, pTM1-BMRF2 or pTM1. Immunoprecipitated proteins were
analysis as indicated. The positions of the proteins discussed in the text are indicated by
Fig. 3. Reactivity of antibody to the carboxyterminus of BDLF2. SDS–PAGE analysis of
proteins immunoprecipitated by antibody to the carboxyterminus of BDLF2 (αBDLF2-C)
from CV-1 cells labeled with [3H] leucine and transfected with pTM1, pTM1-BDLF2 or
pTM1-BMRF2. Immunoprecipitated proteins were mock-digested, digested with
endoglycosidase H (Endo H) or digested with PNGase F before analysis as indicated.
The positions of the proteins discussed in the text are indicated by asterisks.
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differentially processed in the presence of BMRF2
To make an initial characterization of the size of the BDLF2 protein
CV-1 cells were transfected with pTM1-BDLF2 or pTM1, radiolabeled
and immunoprecipitated with αBDLF2-N. The antibody immunopre-
cipitated a diffusely migrating protein of approximately 65 kDa and a
prominent, more tightly migrating protein of 29 kDa (Fig. 2). The
predicted mass of the BDLF2 gene product with no posttranslational
modiﬁcations is approximately 46 kDa. However, were the 6 potential
N-linked glycosylation sites to be used, the protein could be as large
as 65 kDa. To test this possibility immunoprecipitated proteins were
digested with endoglycosidase H which cleaves primarily high
mannose N-linked oligosaccharides and PNGase F which cleaves
high mannose, hybrid and complex oligosaccharides (Maley et al.,
1989). Digestion with either enzyme reduced the 65 kDa protein to
approximately 46 kDa, consistent with the predicted size of an
unglycosylated precursor. The enzymes had no effect on themigration
of the 29 kDa species. Antibody αBMRF2 immunoprecipitated protein
from cells transfected with pTM1-BMRF2 that entered the gel only
minimally. This is consistent with previous studies demonstrating thatFig. 4. Comparison bywestern blotting of BDLF2 expression in the presence and absence of BM
blot with antibody to the aminoterminus of BDLF2 (αBDLF2-N) of CV-1 cells transfected w
panels) western blot of puriﬁed B95-8 virus with antibody to the aminoterminus or car
endoglycosidase H (Endo H) or PNGase F as indicated. The positions of the proteins discussalthough some BMRF2, if extracted from puriﬁed membrane fractions
and run on 7 M urea denaturing gels migrate at around 60 kDa, the
majority of the highly hydrophobic multispan membrane protein
forms high molecular weight oligomers that migrates slower than the
220 kDa marker. It is not solubilized by boiling in the presence of SDS
and reducing agents (Xiao et al., 2007). Consistent with the lack of
N-linked glycosylation sites in the BMRF2 sequence, the oligomers
were also unaffected by digestion with either endoglycosidase.
The antibody to the carboxyterminus of BDLF2 reacted strongly
with a cell protein of almost exactly the same size as the diffusely
migrating 65 kDa species, confounding analysis with this reagent
(Fig. 3). However, it also immunoprecipated the 29 kDa species and
another more diffuse band that spanned the 37 kDa marker. Digestion
with either endoglycosidase H or PNGase F cleared the diffuse bands
at 65 kDa and 37 kDa and revealed a 46 kDa species similar to that
seen with αBDLF2-N and two proteins of approximately 24 kDa and
23 kDa respectively. The slightly faster migration of the 23 kDa protein
after PNGase F digestionwas consistent with the fact that this enzyme
cleaves between the innermost N-acetylglucosamine and aspara-
gine whereas endoglycosidase H cleaves after the innermost N-acet-
ylglucosamine (Maley et al., 1989).
One interpretation of the origin of the 29 kDa species immuno-
precipitated by both αBDLF2-N and αBDLF2-C was that it represents
an N-terminal cleavage product of BDLF2 which includes no N-linked
glycosylation sites. To determine if this were the case cells transfected
with pTM1-BDLF2 were western blotted with αBDLF2-N. The anti-
body reacted with full length glycosylated BDLF2, full length
deglycosylated BDLF2 and the 29 KDa fragment (Fig. 4). The
observation that coexpression of BDLF2 and BMRF2 resulted in the
translocation of BDLF2 from cytoplasmic aggregates to the cell
membrane and the observation that BDLF2 expressed alone carried
no endoglycosidase H-resistant oligosaccharides suggested that in the
absence of BMRF2, BDLF2 was unable to transit from the endoplasmic
reticulum to the Golgi. Western blotting of cells coexpressing BDLF2
and BMRF2 conﬁrmed this. In the presence of BMRF2, BDLF2 carried
both endoglycosidase-sensitive and endoglycosidase-resistant oligo-
saccharides although the 29 kDa fragment was still present. Western
blotting of the native protein in induced Akata cells conﬁrmed the
presence of endoglycosidase-sensitive and endoglycosidase resistant
modiﬁcation and a weak band at 29 kDa also suggested the presence
of the 29 kDa aminoterminal cleavage product (Fig. 4). To determine
what species might be present in virions, virus obtained from the high
producing B95-8/ZHT cell line was puriﬁed by sedimentation through
dextran and western blotted with both αBDLF2-N and αBDLF2-C,
since reactivity with the latter was no longer compromised byRF2 with its expression in virus producing cells or puriﬁed virions. (Left panel) western
ith pTM1-BDLF2, pTM1-BDLF2 and pTM1-BMRF2 or of induced Akata cells; (right two
boxyterminus of BDLF2 (αBDLF2-C). Samples were mock digested or digested with
ed in the text are indicated by asterisks.
Fig. 5. Analysis of BDLF2 under reducing and non-reducing conditions. Western blot
with antibody to the aminoterminus of BDLF2 (αBDLF2-N) of CV-1 cells transfected
with pTM1-BDLF2 and pTM1-BMRF2 electrophoresed under (A) reducing or (B) non-
reducing conditions. Proteins were mock digested or digested with PNGase F before
analysis as indicated.
Fig. 6. Coprecipitation of BMRF2 and BDLF2. SDS–PAGE analysis of proteins
immunoprecipitated by antibodies to the BMRF2 (αBMRF2) from CV-1 cells labeled
with [35S] methionine and transfected with pTM1-BMRF2, pTM1-BMRF2 and pTM1-
BDLF2 or pTM1. Immunoprecipitated proteins were mock-digested or digested with
PNGase F before analysis and immunoprecipitated with preimmune (PB) or immune
(TB) antibodies as indicated. The positions of the proteins discussed in the text are
indicated by asterisks.
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presence of full-length BDLF2 and the aminoterminal 29 kDa fragment
(Fig. 4). AntibodyαBDLF2-C also detected the full length protein and a
proteinwith the samemobility as the diffuse 37 kDa species seen after
immunoprecipitationwith the same antibody. This suggested that this
protein, which was replaced by 23 and 24 kDa species after endogly-
cosidase digestion, was probably a cleaved carboxyterminal fragment
of BDLF2.
Since the proposed aminoterminal fragment, but not the carbo-
xyterminal fragment was immunoprecipitated by antibodies to both
the aminoterminus and the carboxyterminus, the possibility that it
was disulﬁde linked to the full length protein was explored. The
mobility of the fragment was, however, similar on both reducing and
non-reducing gels indicating that it was not (Fig. 5).
BDLF2 interacts directly with BMRF2
The effect of BMRF2 on expression of BDLF2 implied an interaction
between the two proteins. To determine if this were a direct
interaction cells transfected with pTM1-BMRF2 alone or pTM1-
BMRF2 and pTM1-BDLF2 were immunoprecipitated with preimmune
rabbit antibody or αBMRF2. αBMRF2, but not preimmune antibody,
again immunoprecipitated proteins from cells transfected with pTM1-
BMRF2 that remained at the top of the gel. No cross-reactivity had
been seen between αBMRF2 and BDLF2 expressed alone (Fig. 2) or
αBDLF2 and BMRF2 expressed alone (Figs. 2 and 3). However, in cells
cotransfected with pTM1-BMRF2, a protein with the same mobility as
BDLF2 was coprecipitated (Fig. 6). PNGase F digestion increased its
mobility to 46 kDa. A faint band is seen in this gel at 29 kDa, the
position of the proposed aminoterminal cleavage product and in
several other immunoprecipitations such as the second one shown in
the right panel, it was quite prominent. There was, however, no
evidence of the proposed carboxyterminal fragment.
Discussion
There seems to be little doubt that the BDLF2 gene, like its
counterpart in MHV-68, is a type II envelope glycoprotein. Further, it
too, is dependent on the multispan envelope glycoprotein BMRF2 for
authentic processing and transport to the cell surface. BDLF2 and
BMRF2 appear to form a stable complex. Heteromeric complexes of
envelope glycoproteins are common among the herpesviruses and
EBV is no exception. Glycoprotein gH forms a complex with gL
(Yaswen et al., 1993) and gM complexes with gN (Lake et al., 1998). In
both of these cases one of the two partners is essential for authentic
processing and transport of the other. In the absence of gL, gH acquires
no complex sugars consistent with a failure to trafﬁc out of the
endoplasmic reticulum. It is misfolded, judging by its failure to react
with some monoclonal antibodies, and little if any reaches the cell
surface (Li et al., 1995; Wu and Hutt-Fletcher, 2007). In the absence ofgM, gN has no sialic acid added to O-linked N-acetylgalactosamine
residues and it fails to reaches the trans-Golgi (Lake et al., 1998). In
both of these cases, however, as with BMRF2, there are no indications
that transport of gL or gM, is affected by the absence of its partner.
The full length BDLF2 protein migrates as predicted in the absence
of N-linked sugars and the migration of the glycosylated form is
consistent with at least three and possibly all six of the potential
N-linked glycosylation sites being used. However, in addition to full
length BDLF2, antibodies made separately to the amino- and
carboxyterminal regions of the protein immunoprecipitated and
reacted in western blots with smaller species. The aminoterminal
antibody recognized a fragment of approximately 29 kDa which
carries no N-linked sugar. This would be consistent with a cleavage
site downstream of the predicted transmembrane domain at residues
182–208, possibly close to the glycosylation sites at residues 300 and
304, which would also imply that the sites at 258 and 264 are not
accessible to glycosyltransferases. However, the antibody to the
carboxyterminal region of BDLF2 reacts with deglycosylated protein
of approximately 23 kDa which is somewhat larger than would be
expected from a cleavage site so close to the carboxyterminus. Neither
one of the deglycosylated fragments runs exactly as predicted from
the size of the full length form so a more conservative assessment
would be merely that it is likely that the cleavage occurs somewhere
close to the predicted transmembrane domain and that the amino-
terminal fragment may still be inserted in the membrane. Although
programs written to predict proprotein convertase cleavage sites do
not identify one in the context of the entire BDLF2 sequence, there is a
consensus site, KVLR, whichwould be predicted to be cleaved after the
arginine residue at position 225 (Duckert et al., 2004). A cleavage
at this position would again be consistent with the larger size of the
fragment that reacts with the antibody made to the aminoterminus of
the protein, be consistent with the absence of sugar on the 29 kDa
fragment and suggest that it probably includes the transmembrane
domain. Of interest, is the fact that the aminoterminal fragment is
immunoprecipitated by both the aminoterminal and the carboxy-
terminal antibodies while the carboyxterminal fragment is not, even
when BDLF2 is expressed in the absence of other virus proteins. The
carboyxterminal antibody does not react in western blots with the
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a signiﬁcant amount of the fragment is found in the GST-fusion protein
made with residues 213–420 used to make the carboxyterminal
antibody. The more likely explanation is that the aminoterminal
fragment, and not the carboxyterminal fragment, remains associated
with the full length protein in a non-disulﬁde linked interaction. It
cannot be determined with absolute certainty whether the fragments
are biologically relevant or represent some kind of artifact of protein
isolation. They are, however, seen consistently and both are found in
highly puriﬁed virions. In virus, if cleavage does occur prior to
packaging, this would further imply that the carboxyterminal
fragment associates with additional virus proteins.
The importance of the BDLF2 homolog in MHV-68 to intercellular
virus spreadhas beenwell documented (Mayet al., 2005b) and a role for
the complex in manipulating actin and causing outgrowth of long,
branched plasmamembrane fronds has beenproposed (Gill et al., 2008).
We have so far been unable to see such fronds (data not shown) in cells
with documented expression of both BDLF2 and BMRF2 from the
pCAGGS vector under control of the actin promoter (Niwa et al. 1991).
However, the182 residue cytoplasmicdomain of EBVBDLF2 is extremely
long, 107 residues longer than predicted for the Kaposi's sarcoma-
associated herpesvirus homolog and 146 residues longer than the
cytoplasmic domain of MHV-68 gp48. The additional aminoterminal
sequence, which as a cleaved form remains associated with full length
BDLF2 and the BDLF2/BMRF2 complex, is very proline rich and
potentially interactive with other virus or cell proteins. Given the
importance of its partner, BMRF2, to infection of epithelial tissues
(Tugizov et al., 2003; Xiao et al., 2008) further exploration of the role of
BDLF2, theﬁnal EBVenvelope glycoprotein,would seemtobewarranted.
Materials and methods
Cells
Akata, a Burkitt's lymphoma cell line that carries and can be
induced to make EBV (Takada, 1984), and B95-8-ZHT cells (a gift of
Ellen Cahir McFarland, Harvard Medical School), marmoset cells, that
carry the B95-8 strain of EBV and are stably transfected with a plasmid
expressing the BZLF1-4-hydroxytamoxifen dependent mutant estro-
gen receptor fusion protein (B95-8-ZHT) (Johannsen et al., 2004), were
grown in RPMI 1640 (Sigma-Aldrich) supplemented with 10% heat
inactivated fetal bovine serum. CV-1 monkey kidney cells were grown
in Dulbecco's modiﬁed Eagle's medium (Sigma-Aldrich) supplemen-
ted with 5% heat inactivated fetal bovine serum.
Antibodies to GST-fusion proteins
Antibodies weremade by immunization of rabbits with GST-fusion
proteins and were puriﬁed by afﬁnity chromatography on protein
A-agarose (Sigma-Aldrich). Antibody αBDLF2-N was made to GST
fused to the aminoterminal 169 amino acids of BDLF2, αBDLF2-C was
made to GST fused to the carboxyterminal 207 amino acids of BDLF2
and αBMRF2 was made to residues 173–217. All fusions were made in
pGEX-5-X3 (Amersham-GE Health Care).
Plasmids
Plasmids pTM1-BDLF2 and pTM1-BMRF2 were made by cloning
PCR ampliﬁed sequences into the pTM1 vector (Moss et al., 1990)
which contains a T7 promoter, the encephalomyocarditis virus cap-
independent translation signal, a multiple cloning site, and a T7
transcriptional terminator. Translation initiates at the ATG in the NcoI
site in the multiple cloning region. BDLF2 was ampliﬁed with the
5′ primer (GTC GAT GAA CAA GTG GCG G) containing the sequence
directly following the ﬁrst ATG of the ORF and the 3′ primer (CCC AGA
GCT CTA CTG AAC C), which includes the stop codon as well as a SacIsite. The SacI digested PCR product was ligated into pTM1 that had
been digested with NcoI, blunt ended and digested with SacI. For
BMRF2, the 5′ primer (CAT TTA ACA CCA TGG TCT CGT GC) contained
an NcoI site and resulted in a change of the amino acid following the
initiation codon from phenylalanine to valine. The 3′ primer (GAG ACA
GGA CTG AGC TCG TTA GG) included the stop codon and a SacI site.
The NcoI and SacI digested PCR product was ligated into pTM1 that
was digested with both NcoI and SacI.
Virus
Stocks of recombinant vaccinia virus expressing the T7 RNA
polymerase (vvT7) (a gift of William Britt, University of Alabama,
Birmingham) were grown in CV-1 cells infected at a multiplicity of
infection of 0.01 and harvested by freeze-thawing and sonication
of cells. B95-8 virus was harvested from 5 day spent culture me-
dium of B95-8-ZHT cells that had been induced with 200 nM
4-hydroxytamoxifen. Supernatants were clariﬁed by centrifugation
at 800 g for 10min, andﬁltered through a 4 μMﬁlter. Viruswas pelleted
by centrifugation at 4 °C for 2 h at 12,000 g and puriﬁed on dextran T10
gradients by slight modiﬁcation of a previously described procedure
(Johannsen et al., 2004). Brieﬂy, pelleted viruswas resuspended in 2ml
of sodium phosphate buffer pH 8.0, applied to a 35 ml 5–30% dextran
T10 gradient and centrifuged at 76,000 g in an SW48 tube for 1 h at 4 °C.
The virus band was aspirated out, diluted 1:2 in sodium phosphate,
reapplied to a 10 ml 10–30% gradient and centrifuged at 90,000 g for
1 h at 4 °C in an SW41 tube. The virus was aspirated and pelleted at
16,000 g for 1 h at 4 °C in an Eppendorf centrifuge.
Transfection-infection protocol
CV-1 cells were grown to 90% conﬂuency in 100-mm-diameter Petri
dishes and infected with vvT7 at a multiplicity of infection of 5. Thirty-
ﬁve minutes later, the inoculum was removed, and the cells were
washed once in phosphate-buffered saline and transfected with pTM1
plasmids. A total of 14 μg of DNAwasmixed with 60 µl of Lipofectamine
(Invitrogen) made to a total volume of 2.5 ml with serum-free medium.
Each mixture was incubated for 45 min at room temperature before
addition to cells. An additional 1.5ml of medium supplementedwith 6%
heat inactivated fetal bovine serumwas added after 5 h.
Radiolabeling and immunoprecipitation
CV-1 cells infected with vvT7 and transfected with pTM1
plasmids were labeled biosynthetically with 500 μCi of [3H]leucine
(160 Ci/mmol; Amersham-GE Health Care) or 300 μCi [35S] methio-
nine (N1000 Ci/mmol; Amersham-GE Health Care) per dish (approxi-
mately 107 cells) as previously described (Li et al., 1995). Akata cells
were labeled with 100 μCi of [3H] leucine per 106 cells for 20 h at 6 h
after induction with anti-human immunoglobulin G as previously
described (Yaswen et al., 1993). Labeled cells were solubilized in
radioimmunoprecipitation buffer (50 mM Tris–HCl, pH 7.2, 0.15 M
NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate, 0.1 mM phenylmethylsulfonylﬂuoride, and 100 U of Aprotinin
perml), sonicated and immunoprecipitatedwith antibody and protein
A-Sepharose CL4B (Sigma-Aldrich). Immunoprecipitated proteins
were washed, dissociated by heating to 37 °C for 30 min in sample
buffer with 2-mercaptoethanol, and analyzed by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) in 10% poly-
acrylamide cross-linked with bis (EZ-Run™ Protein Gel Solution;
Thermo-Fisher Scientiﬁc) followed by ﬂuorography.
Oligosaccharide digestion
All reagents were obtained from New England BioLabs. Samples
were denatured in Glycoprotein Denaturing Buffer (0.5% SDS, 40 mM
167M. Gore, L.M. Hutt-Fletcher / Virology 383 (2009) 162–167DTT) for 30 min at 37 °C and then digested for 3 h at 37 °C with 250
NEB units of endoglycosidase H in G5 reaction buffer (50 mM sodium
citrate, pH 5.5) or 250 NEB units of PNGase F in G7 reaction buffer
(50 mM sodium phosphate, pH 7.5) with 1% NP-40. Reactions were
stopped by the addition of Laemmli sample buffer and after
incubation for an additional 30 min at 37 °C proteins were analyzed
by SDS–PAGE followed by ﬂuorography.
Western blotting
Cells or virus were lysed in radioimmunoprecipitation buffer,
followed by sonication. Cell lysates were centrifuged at 16,000 g and
oligosaccharide digestionwas carried out as described above. Samples
were then dissociated by boiling in sample buffer with or without
2-mercaptoethanol as indicated, analyzed by SDS–PAGE, and trans-
ferred to PVDFmembranes (0.2 μmpore size; Millipore) at 50 V for 1 h.
Membraneswere blockedwith 5%milk buffer (10mMTris–HCl pH 7.4,
0.15 M NaCl, and 5% fat-free milk). After blocking, the membranes
were reacted with primary antibody for at least 1 h at room tempe-
rature followed by three washes in wash buffer (10 mM Tris–HCl pH
7.4, 0.15 M NaCl 0.3% Tween-20) for 5 min per wash. Donkey anti-
rabbit IgG conjugated to horseradish peroxidase (GE Health Care) was
used at a dilution of 1:50,000 and incubated on themembranes for 1 h
at room temperature. After three washes, membranes were reacted
with the Amersham™ ECL Plus Western Blotting Detection System
(GE Health Care) according to the manufacturer's protocol and results
were visualized by ﬂuorography.
Immunoﬂuorescence
CV-1 cells that had been transfected with pTM1, pTM1-BDLF2,
pTM1-BMRF2 or a mixture of plasmids and infected with vvT7 were
air-dried on slides and ﬁxed for 10 min in ice-cold acetone. Cells were
incubated sequentially for 30 min at 37 °C with 25 µg rabbit antibody
and ﬂuorescein-conjugated goat anti-rabbit IgG (ICN-Cappel). Cells
were washed three times in phosphate buffered saline between each
incubation and mounted in Fluorescent Mounting Medium (KPL)
diluted 1:1 in phosphate buffered saline for examination in a Zeiss-
BioRad Radiance 2000 confocal microscope.
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